标题
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
作者
关键词
-
出版物
Journal of Immunology Research
Volume 2021, Issue -, Pages 1-15
出版商
Hindawi Limited
发表日期
2021-02-24
DOI
10.1155/2021/6661406
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A review of cancer immunotherapy toxicity
- (2020) Lucy Boyce Kennedy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC
- (2020) Takehito Shukuya et al. Journal of Thoracic Oncology
- A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
- (2020) Fathima Zumla Cader et al. NATURE MEDICINE
- Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
- (2020) Etienne Giroux Leprieur et al. Journal for ImmunoTherapy of Cancer
- The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
- (2020) Katarzyna Tomela et al. Life-Basel
- PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
- (2019) Rui Zhao et al. CELL PROLIFERATION
- Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
- (2019) C G Kim et al. ANNALS OF ONCOLOGY
- Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
- (2019) Dongxu Wang et al. Journal of Hematology & Oncology
- Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)
- (2019) Xiang Shi et al. Molecular Medicine Reports
- Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
- (2019) Xiaotong Li et al. Journal for ImmunoTherapy of Cancer
- Application of PD-1 Blockade in Cancer Immunotherapy
- (2019) Xiaomo Wu et al. Computational and Structural Biotechnology Journal
- Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
- (2019) Heng-Huan Lee et al. CANCER CELL
- Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors
- (2019) Xianhe Xie et al. CANCER INVESTIGATION
- Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
- (2019) Hao Wang et al. Journal of Hematology & Oncology
- Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing
- (2019) Lei Zhang et al. Cancer Immunology Research
- Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
- (2019) Yi Zheng et al. Journal for ImmunoTherapy of Cancer
- Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
- (2019) Nicholas D. Klemen et al. Journal for ImmunoTherapy of Cancer
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition
- (2019) Cretella et al. Cancers
- Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
- (2019) Rachel Grosser et al. CANCER CELL
- Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer
- (2019) Jinshuo Fan et al. GENOMICS
- Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity
- (2019) Sitaram et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma
- (2019) Satoshi Nakahara et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
- (2019) Jiefei Han et al. Cancer Immunology Research
- Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab
- (2018) Ann Rita Halvorsen et al. ACTA ONCOLOGICA
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens
- (2018) Mengjia Song et al. Chinese Journal of Cancer Research
- Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
- (2018) Brandon W. Higgs et al. CLINICAL CANCER RESEARCH
- CAR T-cell Therapy: A New Era in Cancer Immunotherapy
- (2018) Miliotou N. Androulla et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics
- (2018) Margarita Udall et al. Diagnostic Pathology
- Inhibitors of the PD-1 Pathway in Tumor Therapy
- (2018) Martin W. LaFleur et al. JOURNAL OF IMMUNOLOGY
- The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function
- (2018) Saige L. Pompura et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
- (2018) Mohamed E. Salem et al. MOLECULAR CANCER RESEARCH
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Immunotherapy of melanoma
- (2018) Iwona Lugowska et al. Wspolczesna Onkologia-Contemporary Oncology
- Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges
- (2018) Marco De Simone et al. Frontiers in Immunology
- Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
- (2018) Mariaelena Capone et al. Journal for ImmunoTherapy of Cancer
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
- (2018) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Cancer immunotherapy with CAR-T cells – behold the future
- (2018) Charlotte Graham et al. CLINICAL MEDICINE
- PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
- (2018) Fatemeh K. Dermani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
- (2018) Muhammad Khan et al. MEDICINE
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
- (2018) Anastasia Constantinidou et al. PHARMACOLOGY & THERAPEUTICS
- Drug response to PD-1/PD-L1 blockade: based on biomarkers
- (2018) Qi Chen et al. OncoTargets and Therapy
- PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
- (2018) David Stenehjem et al. OncoTargets and Therapy
- Topography of cancer-associated immune cells in human solid tumors
- (2018) Jakob Nikolas Kather et al. eLife
- Immune-related adverse events of immune checkpoint inhibitors: a brief review
- (2018) G. Myers Current Oncology
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
- (2018) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
- (2018) A. N. Niemeijer et al. Nature Communications
- Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
- (2018) Kaikai Shen et al. Journal of Thoracic Disease
- CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
- (2018) Monika C. Brunner-Weinzierl et al. Frontiers in Immunology
- Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
- (2018) Tomas Jelinek et al. Frontiers in Immunology
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy
- (2018) Laura Bonanno et al. Journal of Thoracic Oncology
- Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
- (2017) Varun Sasidharan Nair et al. IMMUNOLOGY AND CELL BIOLOGY
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical trials of CAR-T cells in China
- (2017) Bingshan Liu et al. Journal of Hematology & Oncology
- Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
- (2017) Michael A Davies et al. LANCET ONCOLOGY
- Implications of the tumor immune microenvironment for staging and therapeutics
- (2017) Janis M Taube et al. MODERN PATHOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade
- (2017) Jie Bai et al. Oncotarget
- PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis
- (2017) Jiaying Wu et al. Scientific Reports
- Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting
- (2017) Eva Pike et al. BMJ Open
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Cancer prevention from the perspective of global cancer burden patterns
- (2017) Hiroki Nagai et al. Journal of Thoracic Disease
- The Future of Immunotherapy: A 20-Year Perspective
- (2017) David C. Wraith Frontiers in Immunology
- Primary Immunodeficiency Diseases: Current and Emerging Therapeutics
- (2017) Beatriz E. Marciano et al. Frontiers in Immunology
- PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma
- (2017) Jan Budczies et al. OncoImmunology
- Immunotherapy and tumor microenvironment
- (2016) Haidong Tang et al. CANCER LETTERS
- Mass Cytometry: Single Cells, Many Features
- (2016) Matthew H. Spitzer et al. CELL
- Genomic Approaches to Understanding Response and Resistance to Immunotherapy
- (2016) D. A. Braun et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges
- (2016) Chrisann Kyi et al. Immunotherapy
- Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
- (2016) Katharina C. Kähler et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
- (2016) Ludmila Danilova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Pembrolizumab for the treatment of advanced melanoma
- (2016) Michael C. Burns et al. Expert Opinion on Orphan Drugs
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
- (2015) J. Zaragoza et al. BRITISH JOURNAL OF DERMATOLOGY
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
- (2015) Xiangjiao Meng et al. CANCER TREATMENT REVIEWS
- Oral immunotherapy for food allergy: mechanisms and role in management
- (2015) A. Nowak-Węgrzyn et al. CLINICAL AND EXPERIMENTAL ALLERGY
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
- (2015) Hisato Kawakami et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy
- (2015) Mizuki Nishino et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer
- (2015) Christine Mall et al. OncoImmunology
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
- (2014) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perceptions of Cancer Risk and Cause of Cancer Risk in Korean Adults
- (2014) Su Yeon Kye et al. Cancer Research and Treatment
- Opportunistic infections in patients treated with immunotherapy for cancer
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial
- (2013) Christoph Domschke et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- (2012) Esdy N. Rozali et al. Clinical & Developmental Immunology
- Immunotherapy for Primary Immunodeficiency Diseases
- (2012) Philip Wood MEDICAL CLINICS OF NORTH AMERICA
- Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma
- (2012) Pan Weibo et al. MEDICAL HYPOTHESES
- MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1
- (2012) Yongkui Li et al. Protein & Cell
- The role of the PD-1 pathway in autoimmunity and peripheral tolerance
- (2011) Brian T. Fife et al. Annals of the New York Academy of Sciences
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
- (2008) Florian Schuetz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215
- (2008) S. A. Georges et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now